I

I-MAB
D

IMAB

0.93570
USD
-0.02
(-2.25%)
Market Closed
Volume
4,330
EPS
-0
Div Yield
-
P/E
-0
Market Cap
76,260,567
News

Title: I/MAB

Sector: Healthcare
Industry: Biotechnology
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).